Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis

Key Points

• This research aims to analyze the effects of direct oral anticoagulant types and doses in patients with atrial fibrillation and decompensated cirrhosis.
• Propensity-matched analysis conducted on patients with atrial fibrillation and decompensated cirrhosis.
• Evaluated different types and doses of direct oral anticoagulants.
• Primary outcomes included bleeding events and overall clinical outcomes.
• Patients receiving higher doses of direct oral anticoagulants experienced increased bleeding risk (HR 2.5, 95% CI 1.7-3.6, p<0.001).
• Certain types of direct oral anticoagulants showed better clinical outcomes than others (P=0.02).
• Lower doses correlated with fewer adverse events and improved safety profiles.